Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.

Community Practice Connections™: IPF Best Practice: Evolving Paradigms in the Management of Idiopathic Pulmonary Fibrosis: Optimizing Outcomes Through a Team Approach

Release Date: October 31, 2018
Expiration Date: October 31, 2019
Media: Internet - based

Activity Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease with a complicated and challenging diagnosis. This rare interstitial lung disease occurs mostly in individuals ≥ 50 years of age with a mortality rate of nearly 50% in the first 2.5- to 3.5 years, a prognosis worse than most common cancers. Many barriers to early, accurate diagnosis exist, including overlapping symptoms with chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF), and underestimation of symptoms by both clinicians and patients.

In this Community Practice Connections™ expert faculty will review the updated international guidelines for diagnosis and treatment, including advances in the pharmacological management of IPF. Practical strategies that can be implemented to improve the quality of care will be discussed with a special emphasis on tertiary treatment centers and the role of pulmonary rehabilitation.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This program is directed toward pulmonologists, radiologists, primary care physicians, physician assistants, nurse practitioners, nurses, other healthcare providers interested in IPF.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • IDENTIFY the diagnostic criteria that differentiates IPF from other interstitial lung diseases
  • EXPLAIN how to apply current guidelines and new clinical evidence to develop an appropriate management plan for patients with IPF.
  • DESCRIBE components of an individualized treatment plan for patients with IPF

Faculty, Staff, and Planners' Disclosures


Steven D. Nathan, MD
Medical Director, Advanced Lung Disease and Lung Transplant Program
Inova Fairfax Hospital
Falls Church, Virginia

Disclosure: Grant/research support, consultant, member of speakers bureau: Boehringer Ingelheim, Inc. and Roche-Genentech.

Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
University of Florida
Gainesville, Florida
Disclosure: Consultant –Amgen

Disclosure: Grant/research support, consultant, member of speakers bureau: Boehringer Ingelheim, Inc. and Roche-Genentech.

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By